{"id":411801,"date":"2025-11-25T13:30:00","date_gmt":"2025-11-25T12:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=411801"},"modified":"2025-11-03T12:03:03","modified_gmt":"2025-11-03T11:03:03","slug":"enpp1-como-biomarcador-de-mal-pronostico-y-deteccion-precoz-de-metastasis-cerebrales","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/enpp1-como-biomarcador-de-mal-pronostico-y-deteccion-precoz-de-metastasis-cerebrales\/","title":{"rendered":"ENPP1 como biomarcador de mal pron\u00f3stico y detecci\u00f3n precoz de met\u00e1stasis cerebrales"},"content":{"rendered":"\n<p><strong>Alrededor del 15-20% de todos los casos de c\u00e1ncer de mama son HER2-positivos, que es un subtipo con un curso agresivo y una mayor tendencia a la met\u00e1stasis cerebral. Un nuevo estudio demuestra ahora que la enzima <em>ENPP1<\/em>socava la funci\u00f3n de barrera de la barrera hematoencef\u00e1lica (BHE) y puede servir como biomarcador potencial de la fase temprana del desarrollo de met\u00e1stasis cerebrales en el c\u00e1ncer de mama HER2-positivo, lo que significa que <em>los inhibidores de la ENPP1<\/em>pueden utilizarse en el futuro como estrategia complementaria para la prevenci\u00f3n de met\u00e1stasis, especialmente en pacientes con una elevada expresi\u00f3n de ENPP1 y una disfunci\u00f3n demostrada de la BHE. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fenpp1-como-biomarcador-de-mal-pronostico-y-deteccion-precoz-de-metastasis-cerebrales%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Alrededor del 15-20% de todos los casos de c\u00e1ncer de mama son HER2-positivos, que es un subtipo con un curso agresivo y una mayor tendencia a la met\u00e1stasis cerebral. Un&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fenpp1-como-biomarcador-de-mal-pronostico-y-deteccion-precoz-de-metastasis-cerebrales%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411808,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"C\u00e1ncer de mama HER2 positivo  ","footnotes":""},"category":[11475,11478,11364,11369,11328,11336,11552],"tags":[86094,86090,86098,86085],"powerkit_post_featured":[],"class_list":["post-411801","post","type-post","status-publish","format-standard","has-post-thumbnail","category-estudios","category-formacion-continua","category-genetica","category-ginecologia","category-neurologia","category-oncologia","category-rx-es","tag-barrera-hematoencefalica-2","tag-cancer-de-mama-her2-positivo","tag-inhibicion-de-la-enpp1","tag-metastasis-cerebral-2","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-28 11:17:13","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/411801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=411801"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/411801\/revisions"}],"predecessor-version":[{"id":411810,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/411801\/revisions\/411810"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/411808"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=411801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=411801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=411801"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=411801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}